Michael H. Mulroy - 01 Jul 2025 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Role
Director
Signature
/s/ Alexandra Hernandez, as Attorney-in-Fact
Issuer symbol
LCTX
Transactions as of
01 Jul 2025
Net transactions value
$0
Form type
4
Filing time
02 Jul 2025, 21:00:06 UTC
Previous filing
25 Nov 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mulroy Michael H. Director C/O LINEAGE CELL THERAPEUTICS, 2173 SALK AVENUE, SUITE 200, CARLSBAD /s/ Alexandra Hernandez, as Attorney-in-Fact 03 Jul 2025 0001509725

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LCTX Stock Option (Right to Buy) Award $0 +75,000 $0.000000 75,000 01 Jul 2025 Common Shares 75,000 $0.8977 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Will vest and become exercisable on the earlier of July 1, 2026 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer.